Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects

Table 3 Geometric means (percentage of the coefficient of variation) of anti-tetanus toxoid antibody titers taken 14 and 28 days after tetanus toxoid vaccination

Group	n	Baseline titers (U/ml)	Anti-tetanus antibody titers at 14 days post-vaccination (U/ml)	Anti-tetanus antibody titers at 28 days post-vaccination (U/ml)
Group A (vaccines alone on day 1)	20	1.6 (106)	11.4 (88)	9.3 (104)
Group B (vaccines 2 weeks before abatacept)	20	1.9 (76)	10.2 (71)	8.7 (68)^a
Group C (vaccines 2 weeks after abatacept)	19^b	2.3 (76)	5.9 (112)	5.6 (98)
Group D (vaccines 8 weeks after abatacept)	19^c	2.3 (54)	9.0 (79)	7.8 (85)

^an = 19 as one subject discontinued due to an adverse event (this discontinued patient only had samples collected at baseline and day 14). ^bSubject discontinued prior to vaccine administration on day 14 due to toxicology. ^cSubject discontinued prior to vaccine administration on day 56 due to toxicology.

ISSN: 1478-6362